Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

Oncology
Soham PuvvadaDaniel O Persky

Abstract

Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction. Patients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed < 25% involvement. Twenty-eight patients were treated, with a median age of 61 years, median of 3 prior therapies, 49% high-risk disease (Follicular Lymphoma International Prognostic Index, FLIPI), and 39% progressive disease. Three patients did not receive Zevalin due to residual bone marrow involvement. The main toxicities were cytopenias, with 11% febrile neutropenia. The overall response rate (ORR) was 72%, with 45% achieving complete response. With a median follow-up of 73 months, 1-year progression-free survival (PFS) was 38%, and median PFS was 10 months, but median overall survival (OS) was not reached. The study did not reach its primary endpoint of a 1-year PFS of 67.3%. Reasons for this could include low...Continue Reading

References

Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S VelasquezF Cabanillas
Oct 23, 1997·Hematology/oncology Clinics of North America·E J Rodriguez-Monge, F Cabanillas
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanArturo Molina
Mar 5, 2008·Cancer Chemotherapy and Pharmacology·Vincent Launay-VacherUNKNOWN European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Jul 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert MarcusGeorge Stein
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserAnton Hagenbeek
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oliver W PressRichard I Fisher
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Mar 19, 2016·Blood·Brad S Kahl, David T Yang

❮ Previous
Next ❯

Citations

Apr 2, 2019·International Reviews of Immunology·Mahsa EskianNima Rezaei
Dec 23, 2020·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·G F SteynM R van Heerden
Apr 2, 2021·ChemMedChem·Natalia Herrero ÁlvarezJason S Lewis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.